Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| MMAE-d8 | MMAE-d 8 is a deuterated labeled MMAE, a potent mitotic inhibitor and a tubulin inhibitor. Uses: Scientific research. Group: Isotope-labeled compounds. Alternative Names: Monomethyl auristatin E-d8; Deuterated labeled MMAE. CAS No. 2070009-72-0. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-15162A. |  |
| Bi-Mc-VC-PAB-MMAE | Bi-Mc-VC-PAB-MMAE consists ADCs linker (Bi-Mc-Val-Cit-PAB) and potent tubulin inhibitor (MMAE, HY-15162). Bi-Mc-VC-PAB-MMAE is a drug-linker conjugate for ADC. Uses: Scientific research. Group: Signaling pathways. CAS No. 1620837-70-8. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-141833. | |
| Cetuximab MMAE | Cetuximab MMAE is an antibody-drug conjugate (ADC) consisting of the EGFR-targeting humanized monoclonal antibody Cetuximab (HY-P9905) conjugated to VcMMAE (HY-15575). Cetuximab MMAE exhibits antitumor activity[1]. Uses: Scientific research. Group: Signaling pathways. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-171135. | |
| DBCO-PEG4-VC-PAB-MMAE | DBCO-PEG4-VC-PAB-MMAE consists a ADC linker (DBCO-PEG4-VC-PAB) and a tubulin polymerization inhibitor MMAE (HY-15162). DBCO-PEG4-VC-PAB-MMAE can be used in the synthesis of antibody-agent conjugates (ADCs). MMAE is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. DBCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups. Uses: Scientific research. Group: Signaling pathways. CAS No. 2129164-91-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-136314. | |
| DBCO-Val-Cit-PAB-MMAE | DBCO-Val-Cit-PAB-MMAE is a drug-linker conjugate, which can be used for the synthesis of ADC molecules. MMAE (HY-15162) is a tubulin inhibitor, which can be used as an ADC toxin. DBCO-Val-Cit-PAB is the linker with the electrophilic group [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2768446-73-5. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-W591408. | |
| Gly3-VC-PAB-MMAE | Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs)[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2684216-48-4. Pack Sizes: 5 mg; 10 mg. Product ID: HY-131056. | |
| Mal-PEG8-Val-Cit-PAB-MMAE | Mal-PEG8-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Mal-PEG8-Val-Cit-PAB-MMAE contains a cleavable ADC linker and a potent tubulin inhibitor MMAE (HY-15162)[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2353409-69-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-141156. | |
| MC-betaglucuronide-MMAE-1 | MC-betaglucuronide-MMAE-1 is a agent-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide. Uses: Scientific research. Group: Signaling pathways. CAS No. 1703778-92-0. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-136317. | |
| Mc-MMAE | Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a agent-linker conjugate for ADC. Uses: Scientific research. Group: Signaling pathways. Alternative Names: Maleimidocaproyl-monomethylauristatin E. CAS No. 863971-24-8. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15741. | |
| MC-VA-PABC-MMAE | MC-VA-PABC-MMAE is a agent-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162)[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1818864-51-5. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-147239. | |
| mDPR-Val-Cit-PAB-MMAE | mDPR-Val-Cit-PAB-MMAE consists the ADCs linker (mDPR-Val-Cit-PAB) and potent tubulin inhibitor (MMAE), mDPR-Val-Cit-PAB-MMAE is an antibody drug conjugate. Synonyms: N-[(2S)-3-Amino-2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanoyl]-L-valyl-N-{4-[(5S,8S,11S,12R)-11-[(2S)-2-butanyl]-12-(2-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenyl-2-propanyl]amino}-1-methoxy-2 ;-methyl-3-oxopropyl]-1-pyrrolidinyl}-2-oxoethyl)-5,8-diisopropyl-4,10-dimethyl-3,6,9-trioxo-2,13-dioxa-4,7,10-triazatetradec-1-yl]phenyl}-N5-carbamoyl-L-ornithinamide; L-Ornithinamide, N-[(2S)-3-amino-2-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxopropyl]-L-valyl-N5-(aminocarbonyl)-N-[4-[(5S,8S,11S,12R)-12-[2-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenyl ethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-oxoethyl]-4,10-dimethyl-5,8-bis(1-methylethyl)-11-[(1S)-1-methylpropyl]-3,6,9-trioxo-2,13-dioxa-4,7,10-triazatetradec-1-yl]phenyl]-. Grades: ≥95%. CAS No. 1491152-26-1. Molecular formula: C65H100N12O15. Mole weight: 1289.561. |  |
| N3-PEG3-vc-PAB-MMAE | N3-PEG3-vc-PAB-MMAE is a synthesized agent-linker conjugate for ADC that incorporates the MMAE (a tubulin inhibitor ) and 3-unit PEG linker. N3-PEG3-vc-PAB-MMAE shows potent antitumor activity. N3-PEG3-vc-PAB-MMAE is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. Uses: Scientific research. Group: Signaling pathways. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-100874. | |
| SuO-Glu-Val-Cit-PAB-MMAE | SuO-Glu-Val-Cit-PAB-MMAE (NHS-Glutarate-Val-Cit-PAB-MMAE) consists a cleavable ADC linker (SuO-Glu-Val-Cit-PAB) and a potent tubulin inhibitor (MMAE). SuO-Glu-Val-Cit-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs)[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: NHS-Glutarate-Val-Cit-PAB-MMAE. CAS No. 1895916-24-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-130989. | |
| TCO-PEG4-VC-PAB-MMAE | TCO-PEG4-VC-PAB-MMAE is a agent-linker conjugate for ADC. TCO-PEG4-VC-PAB-MMAE contains a cleavable ADC linker (TCO-PEG4-VC-PA) and a potent tubulin inhibitor MMAE (HY-15162)[1]. TCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups. Uses: Scientific research. Group: Signaling pathways. CAS No. 2758671-45-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-148057. | |
| Val-Ala-PAB-MMAE | Val-Ala-PAB-MMAE is a Drug-Linker Conjugate for ADC, consisting of ADC linker (Val-Ala-PAB) and MMAE. MMAE is an effective inhibitor of tubulin. Uses: Scientific research. Group: Signaling pathways. CAS No. 1912408-92-4. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-153032. | |
| Val-Cit-PAB-MMAE | Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization. Uses: Scientific research. Group: Signaling pathways. CAS No. 644981-35-1. Pack Sizes: 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-100374. | |
| VcMMAE | VcMMAE (mc-vc-PAB-MMAE) is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE, a tubulin inhibitor), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). Uses: Scientific research. Group: Signaling pathways. Alternative Names: MC-Val-Cit-PAB-MMAE; mc-vc-PAB-MMAE. CAS No. 646502-53-6. Pack Sizes: 5 mg; 10 mg; 50 mg; 100 mg; 500 mg. Product ID: HY-15575. | |
| Brentuximab | Brentuximab is a monoclonal antibody targeting CD30. Brentuximab is conjugated with monomethyl auristatin E (MMAE) (HY-15162) to form the antibody-drug conjugate Brentuximab vedotin (HY-P99107), which can induce apoptosis in primary effusion lymphoma cells. Brentuximab vedotin exhibits antitumor activity with an IC 50 of 10 nM against human CD30+ cancer cells [1] [2] [3]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 2088770-90-3. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P99151. | |
| DBCO-acid | DBCO-acid is a cleavable ADC linker used in the synthesis of ADC linker DBCO-NHS ester (HY-115524 and HY-115545), and drug-linker conjugates DBCO-PEG-MMAE. Uses: White to light yellow powder to crystal. Synonyms: 11,12-Didehydro-gamma-oxodibenz[b,f]azocine-5(6H)-butanoic acid. Grades: > 98.0 %. CAS No. 1353016-70-2. Molecular formula: C19H15NO3. Mole weight: 305.33. | |
| DBCO-acid | DBCO-acid is a click chemistry reagent used in the synthesis of ADC linker DBCO-NHS ester (HY-115524 and HY-115545), and agent-linker conjugates DBCO-PEG-MMAE (HY-111012 and HY-126690). DBCO-acid contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups [1] [2] [3] [4]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1353016-70-2. Pack Sizes: 10 mg; 50 mg; 100 mg. Product ID: HY-42972. | |
| Disitamab vedotin | Disitamab vedotin (RC48) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against human epidermal growth factor receptor 2 (HER2) conjugated via a cleavable linker to the cytotoxic agent Monomethyl auristatin E (MMAE). Disitamab vedotin enhances antitumor immunity [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: RC48. CAS No. 2136633-23-1. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P9985. | |
| Dov-Val-Dil-OH TFA | Dov-Val-Dil-OH is a useful chemical intermediate for synthesis of auristatin-related compounds, such as Monomethyl auristatin E (MMAE), Auristatins are antimitotic agents which inhibits cell division by blocking the polymerisation of tubulin. Uses: Designed for use in research and industrial production. Additional or Alternative Names: Dov-Val-Dil-OH TFA; Dov-Val-Dil-OH; Dov-Val-Dil-OH; dimethylVal-Val-Dil-COOH. Product Category: Others. Appearance: Solid powder. CAS No. 133120-90-8. Molecular formula: C24H44F3N3O7. Mole weight: 543.63. Purity: >98%. IUPACName: (3R,4S,5S)-4-((S)-2-((S)-2-(dimethylamino)-3-methylbutanamido)-N,3-dimethylbutanamido)-3-methoxy-5-methylheptanoic acid trifluoroacetic acid. Canonical SMILES: CC[C@H](C)[C@H](N(C)C([C@@H](NC([C@@H](N(C)C)C(C)C)=O)C(C)C)=O)[C@H](OC)CC(O)=O.O=C(O)C(F)(F)F. Product ID: ACM133120908. Alfa Chemistry ISO 9001:2015 Certified. |  |
| Enfortumab | Enfortumab is a humanized derived anti- Nectin-4 antibody that can be conjugated with the highly efficient microtubule disruptor MMAE (HY-15162) to generate the antibody drug conjugate (ADC) Enfortumab vedotin (HY-P99016A). Enfortumab can be used for the study of locally advanced and metastatic urothelial carcinoma [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 1448664-46-7. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99016. | |
| Enfortumab vedotin-ejfv | Enfortumab vedotin-ejfv is an anti- Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable maleimidocaproylvaline-citrulline linker (SGD-1006). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1346452-25-2. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P99016A. | |
| Enfortumab vedotin-ejfv (solution) | Enfortumab vedotin-ejfv (solution) is an anti- Nectin-4 antibody-drug conjugate. Enfortumab vedotin-ejfv is a fully humanized IgG1 antibody conjugated to the microtubule disrupting agent MMAE (HY-15162) via a protease-cleavable maleimidocaproylvaline-citrulline linker (SGD-1006). Nectin-4 is an adhesion protein involved in cellular processes and tumorigenesis, and Enfortumab vedotin-ejfv is indicated for the inhibition of locally advanced or metastatic urothelial carcinoma [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 1346452-25-2. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P99016B. | |
| Glembatumumab | Glembatumumab is a human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be linked to monomethyl auristatin E (MMAE) to form Glembatumumab vedotin, an ADC for cancer therapy. Synonyms: Anti-GPNMB. CAS No. 1020264-78-1. | |
| Glembatumumab vedotin | Glembatumumab vedotin (CDX-011) is an ADC ( antibody-drug conjugates (ADCs) ) comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CDX-011; CR011-vcMMAE. CAS No. 1182215-65-1. Pack Sizes: 1 mg; 5 mg. Product ID: HY-141604. | |
| Ladiratuzumab | Ladiratuzumab (hLIV22) is an anti- LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer [1] [2]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: hLIV22. CAS No. 1629760-28-6. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99682. | |
| Ladiratuzumab vedotin | Ladiratuzumab vedotin (SGN-LIV1A) is a LIV-1 targeting antibody drug conjugate (ADC) (IC 50 : 5.6 nM for LIV-1). Ladiratuzumab vedotin consists of humanized IgG1 monoclonal antibody, MMAE and a protease-cleavable linker. Ladiratuzumab vedotin can drive immunogenic cell death (ICD) to elicit an immune response. Ladiratuzumab vedotin can be used for research of breast cancer [1] [2] [3] [4]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: SGN-LIV1A. CAS No. 1629760-29-7. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99683. | |
| Lifastuzumab | Lifastuzumab is a humanized anti- NaPi2b monoclonal antibody (IgG1 type). Lifastuzumab can be coupled with monomethyl auristatin E (MMAE) through ADC Linker to form an antibody-drug conjugate (ADC) lifastuzumab vedotin (DNIB0600A) with anticancer activity [1]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 1615697-16-9. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P99970. | |
| MC-Val-Cit-PAB | MC-Val-Cit-PAB is a cleavable ADC Linker that forms part of VcMMAE (HY-15575). VcMMAE is Drug-Linker Conjugates for ADCs. The ADC Cytotoxin in VcMMAE is MMAE, a tubulin polymerization inhibitor. Uses: Scientific research. Group: Signaling pathways. CAS No. 159857-80-4. Pack Sizes: 5 mg; 10 mg; 100 mg; 250 mg; 500 mg; 1 g. Product ID: HY-78738. | |
| Monomethyl auristatin E | Monomethyl auristatin E (MMAE; SGD-1010) is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) to treat several different cancer types. Uses: Scientific research. Group: Signaling pathways. Alternative Names: MMAE; SGD-1010; Vedotin. CAS No. 474645-27-7. Pack Sizes: 5 mg; 10 mg; 50 mg; 100 mg; 250 mg; 500 mg. Product ID: HY-15162. | |
| Monomethyl auristatin E (Standard) | Monomethyl auristatin E (MMAE) (Standard) is the analytical standard of Monomethyl auristatin E (HY-15162). This product is intended for research and analytical applications. Monomethyl auristatin E is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. MMAE is widely used as a cytotoxic component of antibody-drug conjugates (ADCs) against several different cancer types[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: MMAE (Standard); SGD-1010 (Standard); Vedotin (Standard). CAS No. 474645-27-7. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15162R. | |
| Polatuzumab vedotin | Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin has the potential for the research of Large B-cell lymphomas (LBCL) [1]. Uses: Scientific research. Group: Inhibitory antibodies. CAS No. 1313206-42-6. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-132253. | |
| Polatuzumab vedotin (solution) | Polatuzumab vedotin solution is an antibody-drug conjugate targeting CD79b. It contains a humanized anti-CD79b IgG1 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule inhibitor. Polatuzumab vedotin solution has the potential for the research of Large B-cell lymphomas (LBCL) [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1313206-42-6. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-132253A. | |
| SGN-B6A | SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162)[1]. Uses: Scientific research. Group: Signaling pathways. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-164957. | |
| Sofituzumab vedotin | Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti- MUC16 antibody-drug conjugate ( ADC ) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer [1]. Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: DMUC5754A. CAS No. 1418200-58-4. Pack Sizes: 1 mg; 5 mg. Product ID: HY-P99593. | |
| Telisotuzumab vedotin | Telisotuzumab vedotin (ABBV-399) is an antibody-drug conjugate ( ADCs ) targeting c-Met. Telisotuzumab vedotin consists of Monomethyl Auristatin E (MMAE), Telisotuzumab antibody and a cleavable mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used to study non-small cell lung cancer expressing c-Met protein [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ABBV-399. CAS No. 1714088-51-3. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-141601. | |
| Tisotumab vedotin | Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1418731-10-8. Pack Sizes: 1 mg; 5 mg. Product ID: HY-152963. | |
| Trastuzumab vedotin | Trastuzumab vedotin (MRG002) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab vedotin is composed of a humanized anti-HER2 antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab vedotin can be used for the research of HER2-positive breast cancer[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: MRG002; Trastuzumab MMAE. Pack Sizes: 1 mg; 5 mg; 10 mg; 25 mg. Product ID: HY-164992. | |
Our database is helping our users find suppliers everyday.
